Even as weight-loss drugs such as Wegovy and Zepbound explode in popularity, many Americans struggle to afford them.

A new study is out that compares the effectiveness of two popular weight loss drugs, Wegovy and Zepbound. The study, which ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical ...

Doctors say early obesity intervention can help prevent later health problems. But prescribing GLP-1s, such as Ozempic and ...

About 42% of U.S. adults are obese, the CDC says. GLP-1 medications have changed the picture for people hoping to reduce ...

The jump in prescription fills comes despite limited insurance coverage and high out-of-pocket costs for Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound.

Millions of Americans with obesity would be eligible to have popular weight-loss drugs like Wegovy or Ozempic covered by ...

It appears not all weight-loss drugs are created equal. The users of one drug report more weight loss comparted to another ...

Millions of Americans with obesity would be eligible to have popular drugs used for weight loss like Wegovy or Ozempic ...

The costly proposal from the US Department of Health and Human Services sets the stage for a potential showdown between the powerful pharmaceutical industry and Robert F. Kennedy Jr., an ...

such as Wegovy and Zepbound, has ushered in a new era in weight management. While these drugs can lead to significant weight loss, researchers and medical professionals have raised concerns about ...